馃嚫馃嚜 Hansa Biopharma AB
HNSA.STFundamentals
Gross Margin
62.4%
Op. Margin
-
Net Margin
-
ROIC
-
Rev Growth
29.7%
Valuation
Price
46.16 SEK
Day
-0.22%
52-Week Range
23.52 - 48.22
Market Cap
4.6B SEK
Fwd P/E
-
EV/EBITDA
-
Div Yield
-
Annual income statement #
Hansa Biopharma AB annual revenue, operating income and net income in SEK, 2016 to 2025. Revenue was 222.3m in 2025.
| Year | Revenue (SEK) | Operating income | Net income | Net margin |
|---|---|---|---|---|
| 2025 | 222.3m | -520.7m | -534.1m | |
| 2024 | 171.3m | -637.9m | -807.2m | |
| 2023 | 134.1m | -788.5m | -831.7m | |
| 2022 | 154.5m | -576.1m | -611.1m | |
| 2021 | 33.9m | -539.6m | -548.3m | |
| 2020 | 6.1m | -425.1m | -420.9m | |
| 2019 | 3.4m | -357.6m | -360.0m | |
| 2018 | 3.4m | -246.5m | -248.0m | |
| 2017 | 3.4m | -176.1m | -176.7m | |
| 2016 | 2.6m | -111.1m | -111.1m |
Financial Data #
Segment Breakdown #
Peers #
ALVIO.PA EGTX.ST VLA.PA ALCLS.PA VICO.ST GNFT.PA TNG.PA PHARM.AS DBV.PA ORY.MC 路
Compare in Screener
Dividends
Bubble
Short Interest #
Current: 1.49% 路
30d ago: 2.18% 路
All-time high: 4.13% (2026-05-29)
Events #
| Date | Type | Details | Price | Amount |
|---|